Search the Newsreel

MaxCyte Gets A Genentech Nod, But Revenue Still Comes In Chunks

MaxCyte (NASDAQ: MXCT), a cell-engineering company, has reiterated its 2026 revenue guidance of $30-$32 million, driven by high-margin consumables and Strategic Platform License (SPL) milestones. The company recently secured a multi-platform technology license partnership with Genentech, boosting its credibility and potential for enterprise deals. …

MaxCyte (MXCT) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer-Maher Masoud Chief Financial Officer-Parmeet Ahuja Senior Director of Business Development-Sean Menarguez Investor Relations-Erik Abdo Full Conference Call Transcript Operator: Good day. Thank you …

MaxCyte (MXCT) Earnings Reading: EPS Prints Above Forecast in the Latest Session; Stock Move

MaxCyte launches base editor off-target nomination assays

MaxCyte Inc. (NASDAQ:MXCT) has introduced two new off-target nomination assays, CHANGE-seq-BE and ONE-seq-BE, for base editors through its SeQure service. These assays are designed to help therapeutic developers identify and prioritize off-target sites, aligning with regulatory guidance like that from the FDA on genome …

MaxCyte, Inc. Revenue Breakdown – NASDAQ:MXCT

MaxCyte, Inc. (NASDAQ: MXCT) generated $33.03 million USD in revenue last year. Its top-performing segment, PA Revenue, contributed $11.89 million USD, a decrease from the $14.01 million USD in the previous year. The United States was the largest regional contributor, accounting for $21.08 million …

MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Marks a 15.97% EPS Beat, Yet Shares Slip 5.04% - Earnings Sentiment Score

MaxCyte (MXCT) Q2 2026 Earnings Call: Guidance Reaffirmed as Genentech Partnership Expands

MaxCyte reported Q2 2026 total revenue of $7.3 million, a 15% decrease year-over-year, yet reaffirmed its full-year 2026 revenue guidance of $30 million to $32 million, anticipating low-single-digit growth in the second half. The company highlighted a new enterprise-level partnership with Genentech, which expands …

MaxCyte (MXCT) Stock Price Reflects Faith In Royalties Over Core Weakness

MaxCyte (MXCT) stock slipped despite beating Q2 revenue expectations, with the market focusing on its high gross margins and cash balance. The company's future hinges on its cell engineering bets and royalty streams from partnerships, while core revenue remains soft. Investors are weighing the …

Teleconferência de Resultados do 2T26 da MaxCyte (MXCT): Guidance Reafirmado com a Expansão da Parceria com a Genentech

MaxCyte reported Q2 2026 total revenue of $7.3 million, a 15% year-over-year decrease but exceeding expectations due to sequential growth in instrument allocations and processing assembly demand. The company reaffirmed its full-year revenue guidance of $30 million to $32 million, anticipating low single-digit growth …

Conferencia de resultados del T2 de 2026 de MaxCyte (MXCT): Se reafirman las proyecciones a medida que se amplía la alianza con Genentech

MaxCyte (MXCT) reportó ingresos totales de $7.3 millones en el segundo trimestre de 2026, una disminución del 15% interanual, pero reafirmó sus proyecciones anuales de ingresos entre $30 y $32 millones. La empresa destacó una nueva alianza multiplataforma con Genentech, que abarca múltiples programas …

Stifel Nicolaus Keeps Their Buy Rating on MaxCyte (MXCT)

MaxCyte revenue down 15% to USD 7.3M in Q2 2026

MaxCyte, Inc. reported its Q2 2026 financial results, showing a 15% decrease in total revenue to $7.3 million compared to Q2 2025. Despite the revenue dip, the company exceeded expectations due to strong instrument placements and stable processing assembly sales, and significantly reduced its …

MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 153.3% in the first quarter, acquiring an additional 1.206 million shares to own a total of 1.993 million shares, representing 1.86% of the company. Other institutional investors also built positions, with hedge …

Price to sales forward of MaxCyte, Inc. – MUN:MYE0

This page from TradingView provides financial information for MaxCyte, Inc. (MUN:MYE0), specifically focusing on its forward price-to-sales ratio. The article indicates that market data is provided by ICE Data Services and reference data by FactSet, with SEC filings from Quartr.

MaxCyte Q2 Results: EPS beats estimates, revenue falls 14.5% YoY

MaxCyte Inc. reported Q2 2026 results, with EPS beating estimates at $(0.08) despite a 14.53% year-over-year revenue decrease to $7.271 million. The company narrowed its net loss by 33.33% and announced a new strategic partnership with Genentech. MaxCyte also reaffirmed its full-year 2026 revenue …

MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...

MaxCyte Inc. reported a 15% decrease in total revenue for Q2 2026, reaching $7.3 million, with core revenue down 21%. Despite this, the company exceeded expectations and highlighted significant growth in CASGEVY royalties and a new enterprise-level partnership with Genentech to diversify revenue streams. …

MaxCyte (MXCT) Earnings Call Signals Stabilizing Turnaround

MaxCyte narrows Q2 2026 loss 28%, signs Genentech deal

MaxCyte (NASDAQ:MXCT) Issues Earnings Results

MaxCyte (NASDAQ:MXCT) reported a slight beat on earnings with an adjusted loss of $0.08 per share against an expected $0.09 loss, and revenue of $6.5 million, largely meeting estimates. The company reaffirmed its 2026 revenue guidance of $30 million–$32 million, anticipating instrument placements to …

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

MaxCyte, Inc. (MXCT) reported a Q2 loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.12 loss, and surpassed revenue estimates with $7.27 million. Despite beating earnings and revenue expectations in some recent quarters, the stock has underperformed the market this …

Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall

MaxCyte reported Q2 2026 revenue of $7.3 million, exceeding analyst expectations, though shares fell after hours due to a year-over-year sales decline and lower margins. The company highlighted stabilization in the cell therapy market and a new enterprise partnership with Genentech as key developments. …

$MXCT ($MXCT) Releases Q2 2026 Earnings

MaxCyte Reports Second Quarter 2026 Financial Results

MaxCyte, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting total revenue of $7.3 million, a 15% decrease year-over-year, and a net loss of $8.9 million, an improvement from the $12.4 million loss in Q2 2025. The company reiterated …

MXCT Q1 2026 Earnings: EPS Surprise of 50.98% Delivers Narrower Loss, Shares Rise 2.48% - Earnings Analysis

Tranche Update on MaxCyte, Inc.'s Equity Buyback Plan announced on May 12, 2026.

MaxCyte, Inc. has provided an update on its equity buyback plan announced on May 12, 2026. As of August 12, 2026, the company has repurchased 4,730,105 shares, representing 4.42% of its stock, for a total of $5.5 million. This repurchase completes the program initiated …

MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates as Shares Rise 6.31% - Financial Summary

MaxCyte, Inc. (MXCT) reported a Q2 loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.12 loss, and surpassed revenue estimates with $7.27 million. Despite beating earnings and revenue expectations in some recent quarters, the stock has underperformed the market this …

MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates as Shares Rise 6.31% - Revenue Estimate Trend

MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates as Shares Rise 6.31% - Segment Revenue Breakdown

MaxCyte, Inc. (MXCT) reported a Q2 loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.12 loss, and surpassed revenue estimates with $7.27 million. Despite beating earnings and revenue expectations in some recent quarters, the stock has underperformed the market this …

MaxCyte Inc (NASDAQ: MXCT) Stock Price, News & Analysis

MaxCyte | 4: Statement of changes in beneficial ownership of securities-Director Johnston John Joseph

This document is a statement of changes in beneficial ownership of securities for Director Johnston John Joseph at MaxCyte. These types of filings are routine disclosures required for company insiders. The specific details of the changes in ownership are contained within the document.

Latest MXCT ETF News Today | Earnings, Events & Price Alerts

This page provides the latest news and updates for MXCT ETF, including earnings reports, significant partnerships, and strategic developments. Recent headlines cover MaxCyte's collaborations with Genentech and Adicet Bio, Q4 2025 earnings results and forecasts for 2026 revenue, and executive appointments. The company has …

MaxCyte (MXCT) Expected to Post Earnings on Wednesday

River Global Investors Discloses Investment at MaxCyte with 0.78% Stake

River Global Investors LLP has disclosed a 0.78% stake in MaxCyte, Inc. common stock as of July 31, 2026. This change in holdings follows a corporate restructuring at River Global Investors' parent company, with Liontrust Investment Partners LLP assuming responsibility for certain funds and …